Press Release

October 14, 2020
1 min read

Copanlisib regimen extends PFS in lymphoma subset


Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The addition of copanlisib to rituximab extended PFS among patients with relapsed indolent non-Hodgkin lymphoma who received prior rituximab-containing therapy, according to topline data released by the agent’s manufacturer.

Copanlisib (Aliqopa, Bayer), a PI3 kinase inhibitor, received FDA approval in 2017 for treatment of adults with relapsed follicular lymphoma who received at least two prior systemic therapies.

The randomized phase 3 CHRONOS-3 trial included 458 patients with relapsed indolent non-Hodgkin lymphoma who relapsed after at least one prior line of rituximab-containing therapy. Most patients had follicular lymphoma, marginal zone lymphoma, small lymphocytic lymphoma or lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia.

Researchers assigned patients to rituximab with either copanlisib or placebo.

The double-blind trial met its primary endpoint, as patients assigned the copanlisib regimen achieved significantly longer PFS.

The copanlisib-rituximab combination exhibited a safety profile consistent with previously published data on each agent alone. Researchers observed no new safety signals.

“Indolent forms of non-Hodgkin lymphoma are a heterogenous group of malignancies characterized by a chronic pattern of remissions and recurrences,” Scott Z. Fields, MD, senior vice president and head of oncology development at Bayer, said in a company-issued press release. “For [patients with indolent non-Hodgkin lymphoma] with disease progression who are in need of treatment, there are few approved treatment options. The positive results from CHRONOS-3 demonstrate the potential clinical benefit of copanlisib in combination with rituximab to address the unmet medical need in these patients.”

Complete results of CHRONOS-3 will be presented at a scientific meeting, and Bayer officials intend to discuss the findings with regulatory authorities.